Aegerion Pharmaceuticals, Inc.
) recently received a positive opinion from the Committee for
Medicinal Products for Human Use (CHMP) for Lojuxta
The company is looking to get Lojuxta approved in the EU as an
adjunct to a low-fat diet and other lipid-lowering medicinal
products with or without low density lipoprotein (LDL) apheresis
in adults with homozygous familial hypercholesterolemia
The Lojuxta marketing application was submitted for approval
in the EU in the first quarter of 2012. A final decision on
Lojuxta should be out in the third quarter of 2013. With the CHMP
adopting a positive opinion, we expect Lojuxta to gain EU
We note that Lojuxta is already available in the US under the
trade name Juxtapid. Net product sales for the first quarter 2013
were $1.2 million.
We are encouraged with the progress of Aegerion's Juxtapid in
the HoFH market. We expect investor focus to remain on the sales
ramp up of Juxtapid. Aegerion expects 250 to 300 patients to be
on Juxtapid therapy worldwide in 2013. We note that Kynamro,
approved in the US in Jan 2013, has also entered the HoFH
Currently, companies like
Regeneron Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
) are also looking to enter the hypercholesterolemia market
In Feb 2013, Alnylam Pharma joined hands with
The Medicines Company
) forming an exclusive global alliance to develop and
commercialize Alnylam's ALN-PCS RNAi therapeutic program for the
treatment of hypercholesterolemia.
Aegerion carries a Zacks Rank #3 (Hold). Currently, Alnylam
looks well positioned with a Zacks Rank #2 (Buy).
AEGERION PHARMA (AEGR): Free Stock Analysis
ALNYLAM PHARMA (ALNY): Free Stock Analysis
MEDICINES CO (MDCO): Free Stock Analysis
REGENERON PHARM (REGN): Free Stock Analysis
To read this article on Zacks.com click here.